Three-year Outcomes in de Novo Liver Transplant Patients Receiving Everolimus with Reduced Tacrolimus: Follow-Up Results from a Randomized, Multicenter Study

Transplantation

Volumn 99, Issue 7, 2015, Pages 1455-1462

  Fischer, Lutz ^a   Saliba, Faouzi ^b   Kaiser, Gernot M ^c   De Carlis, Luciano ^d   Metselaar, Herold J ^e   De Simone, Paolo ^f   Duvoux, Christophe ^g   Nevens, Frederik ^h   Fung, John J ⁱ   Dong, Gaohong ^j   Rauer, Barbara ^j   Junge, Guido ^j  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g HENRI MONDOR HOSPITAL   (France)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ADVERSE OUTCOME; ALCOHOL LIVER CIRRHOSIS; ANEMIA; ARTICLE; ASCITES; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCISIONAL HERNIA; INTERSTITIAL LUNG DISEASE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; MYCOSIS; NEOPLASM; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS INFECTION; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; EUROPE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; RISK FACTOR; TIME FACTOR;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; EVEROLIMUS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938883170     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000555     Document Type: Article

References (19)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931.
2. Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl. 2009;15:1142.
3. Saner FH, Cicinnati VR, Sotiropoulos G, Beckebaum S. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation. Liver Int. 2012;32:179.
4. Neuberger JM, Mamelok RD, Neuhaus P, et al.; ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 2009;9:327.
5. Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant. 2011;11:965.
6. Goralczyk AD, Bari N, Abu-Ajaj W, et al. Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantation: a systematic review of randomized controlled trials. Am J Transplant. 2012;12:2601.
7. Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997;64:32.
8. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10:2252.
9. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant. 2012;12:1855.
10. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008.
11. Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734.
12. Garces G, Contreras G, Carvalho D, et al. Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus. Clin Nephrol. 2011;75:150.
13. Lee JP, Heo NJ, Joo KW, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant. 2010;25:2772.
14. Euvrard S, Boissonnat P, Roussoulières A, et al. Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients. Transpl Int. 2010;23:855.
15. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012; 12:1146.
16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl JMed. 1996;334:693.
17. Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004;10:911.
18. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604.
19. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658.